Biostate AI

Biostate AI is a biodata foundry startup that develops technologies for scalable multiomic data collection, scientific discovery, and AI training in the healthcare sector. The company offers two primary service products: Total RNA sequencing and OmicsWeb Copilot for RNAseq data analysis. Biostate AI's Total RNA sequencing utilizes its patent-pending Barcode-Integrated Reverse Transcription (BIRT) technology to provide affordable and comprehensive analysis of all RNA types, including non-coding RNAs such as long non-coding RNAs, micro RNAs, circular RNAs, and enhancer RNAs. This approach surpasses traditional RNA sequencing methods that typically focus only on messenger RNA. The company's OmicsWeb Copilot is a conversational AI tool that employs large-language models to assist biologists in analyzing and visualizing RNAseq data. It offers access to over 1,000 unique RNAseq datasets collected by Biostate AI and is being fine-tuned on 5,000 proprietary datasets to enhance its analysis capabilities and anomaly detection. Biostate AI's ultimate goal is to develop AI that can predict human and animal health changes, including toxicity and efficacy responses to drugs. In a recent demonstration, the company showed that RNA expression in blood taken from rats before drug dosing could predict survival with a Hazard Ratio of 8. Biostate AI has filed nine pending patents on its technologies and has exclusively in-licensed intellectual property from the California Institute of Technology to expand its biomolecule analysis capabilities.

Key customers and partnerships

Biostate AI collaborates with academic researchers, hospital biorepositories, and pharmaceutical and biotech companies. The company has established partnerships with industry leaders, including Twist Bioscience, for new technology development. Biostate AI offers its OmicsWeb Copilot platform at no cost to academic and nonprofit users and researchers. The company's technologies aim to reduce the amount of animal testing performed by pharmaceutical and biotech companies in preclinical studies.